Acrivon Therapeutics

IPO

Acrivon Therapeutics is a biotech company in Watertown, United States, founded in 2018. It has raised $230.0M across 2 rounds, most recently a $130.0M Venture Round in April 2024.

Precision oncology powered by proteomics

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$230.0M
Last Round
$130.0M Venture RoundApr 2024
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 12 investors for this company. The full record is or through the API.

About

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary Acrivon Precision Predictive Proteomics (AP3) platform. The AP3 platform enables unprecedented patient selection by profiling the activity of key cancer-driving proteins at the individual tumor level, identifying which patients are most likely to respond to a given targeted therapy. Headquartered in Watertown, Massachusetts, Acrivon is advancing a pipeline of precision oncology drug candidates, including ACR-368, a CHK1/2 inhibitor being evaluated in endometrial and ovarian cancers.

Summary

It lists 51–200 employees. It has raised $230.0M in total across 2 rounds, most recently a $130.0M Venture Round in Apr 2024. Investors include Morgan Stanley, Jefferies and Cowen.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
Venture RoundVenture UnknownApr 2024
$130.0M

Sign up to see all 3 events

Funding: Series B through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Acrivon Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/acrivon-therapeutics"><img src="https://indexed.vc/api/badge/company/acrivon-therapeutics" alt="Acrivon Therapeutics on Indexed.vc" width="260" height="76" /></a>